BIS Performance — ProShares UltraShort Nasdaq Biotechnology
Data updated: 2026-08-14
BIS returned −11.50% year to date and −54.78% over one year to May 2026. Annualised returns are −23.89% over 3 years and −15.78% over 5 years. The fund trailed its Trading - Leveraged category average: $100 invested three years ago grew to $44, against $173 for the category, and to $45 over one year, against $137. Volatility over the past three years was 30.99% a year. In the 12 months to May 2026 the fund took in a net $1.7M, and assets reached $2.42M.
BIS Growth of $100
What $100 invested in ProShares UltraShort Nasdaq Biotechnology grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Trading - Leveraged category average over the same months.
| Period | BIS | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $45 | $137 |
| 3 years (Jun 2023 – May 2026) | $44 | $173 |
| 5 years (Jun 2021 – May 2026) | $42 | $155 |
| Since data start (Sep 2019 – May 2026) | $12 | $181 |
BIS Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | −11.50% |
| 1 year | −54.78% |
| 3 years (annualised) | −23.89% |
| 5 years (annualised) | −15.78% |
BIS Annual Returns
Calendar-year total returns of ProShares UltraShort Nasdaq Biotechnology, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | −11.50% |
| 2025 | −46.10% |
| 2024 | +5.01% |
| 2023 | −6.34% |
| 2022 | −2.54% |
| 2021 | −14.79% |
| 2020 | −55.99% |
| 2019 (Sep–Dec) | −28.42% |
BIS Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −5.3% | −6.2% | +5.5% | −0.9% | −4.7% | — | — | — | — | — | — | — |
| 2025 | −9.3% | +0.5% | +13.2% | −4.1% | +6.6% | −6.7% | −10.3% | −9.0% | −8.2% | −17.1% | −15.1% | +4.0% |
| 2024 | −0.2% | −2.0% | +0.4% | +13.6% | −10.5% | −6.1% | −11.6% | −1.5% | +5.1% | +5.7% | −0.2% | +16.1% |
| 2023 | −6.7% | +14.1% | −2.9% | −2.7% | +5.7% | +0.2% | −2.1% | +1.3% | +8.9% | +14.6% | −9.1% | −21.9% |
| 2022 | +25.5% | +6.5% | −10.3% | +20.2% | −1.7% | −5.3% | −8.9% | +0.2% | +2.6% | −17.1% | −11.3% | +5.5% |
| 2021 | −12.5% | +3.5% | +5.5% | −6.5% | +2.9% | −15.2% | −0.6% | −9.5% | +9.4% | +2.9% | +7.3% | +0.6% |
| 2020 | +11.8% | −2.0% | −3.9% | −27.7% | −17.0% | −5.0% | +1.9% | −3.0% | −2.3% | +5.8% | −20.8% | −9.3% |
| 2019 | — | — | — | — | — | — | — | — | +6.4% | −14.2% | −20.0% | −1.9% |
BIS Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 30.99%
- 3-year Sharpe ratio: -0.92 (vs 4.5% risk-free rate)
- Best month: +16.05% (Dec 2024)
- Worst month: −21.86% (Dec 2023)
BIS Fund Flows
Monthly money in and out of ProShares UltraShort Nasdaq Biotechnology, from SEC Form N-PORT.
- 12-month net flow: $1.7M
- 12-month gross sales (incl. reinvestments): $2.3M
- Sales ÷ redemptions: 3.68×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $86K | $0 | $86K |
| Apr 2026 | $0 | $0 | $0 |
| Mar 2026 | $0 | $0 | $0 |
| Feb 2026 | $88K | $258K | −$170K |
| Jan 2026 | $176K | $0 | $176K |
| Dec 2025 | $185K | $0 | $185K |
| Nov 2025 | $766K | $0 | $766K |
| Oct 2025 | $122K | $0 | $122K |
| Sep 2025 | $134K | $0 | $134K |
| Aug 2025 | $0 | $0 | $0 |
| Jul 2025 | $0 | $0 | $0 |
| Jun 2025 | $717K | $359K | $358K |
BIS Assets Under Management
Net assets of ProShares UltraShort Nasdaq Biotechnology by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $2.42M |
| 2026-02-28 | $2.36M |
| 2025-11-30 | $2.41M |
| 2025-08-31 | $2.47M |
| 2025-05-31 | $2.88M |
| 2025-02-28 | $3.34M |
| 2024-11-30 | $3.51M |
| 2024-08-31 | $3.20M |
| 2024-05-31 | $3.50M |
| 2024-02-29 | $4.34M |
| 2023-11-30 | $4.57M |
| 2023-08-31 | $4.57M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.